VYGR

Company Overview — What Does Voyager Therapeutics, Inc. Do?

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts. Voyager Therapeutics, Inc. (VYGR) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Alfred W. Sandrock and employs approximately 100 people, headquartered in Cambridge, Massachusetts. With a market capitalization of $238M, VYGR is one of the notable companies in the Healthcare sector.

Voyager Therapeutics, Inc. (VYGR) Stock Rating — Reduce (April 2026)

As of April 2026, Voyager Therapeutics, Inc. receives a Reduce rating with a composite score of 30.6/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.VYGR ranks #2,897 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Voyager Therapeutics, Inc. ranks #409 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

VYGR Stock Price and 52-Week Range

Voyager Therapeutics, Inc. (VYGR) currently trades at $3.74. The stock lost $0.22 (5.6%) in the most recent trading session. The 52-week high for VYGR is $5.55, which means the stock is currently trading -32.6% from its annual peak. The 52-week low is $2.65, putting the stock 41.3% above its annual trough. Recent trading volume was 525K shares, suggesting relatively thin trading activity.

Is VYGR Overvalued or Undervalued? — Valuation Analysis

Voyager Therapeutics, Inc. (VYGR) carries a value factor score of 13/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.20x, versus the sector average of 2.75x. The price-to-sales ratio is 4.75x, compared to 1.66x for the average Healthcare stock.

At current multiples, Voyager Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Voyager Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Voyager Therapeutics, Inc. (VYGR) earns a quality factor score of 23/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -51.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -40.2% versus the sector average of -33.1%.

On a margin basis, Voyager Therapeutics, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -381.3% (sector: -66.1%). Net profit margin stands at -341.7%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -54.8% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

VYGR Debt, Balance Sheet, and Financial Health

Voyager Therapeutics, Inc. has a debt-to-equity ratio of 29.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 7.64x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $45M.

VYGR has a beta of 1.36, meaning it is more volatile than the broader market — a $10,000 investment in VYGR would be expected to move 36.2% more than the S&P 500 on any given day. The stability factor score for Voyager Therapeutics, Inc. is 30/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Voyager Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Voyager Therapeutics, Inc. reported revenue of $50M and earnings per share (EPS) of $-2.04. Net income for the quarter was $-101M. Gross margin was 100.0%. Operating income came in at $-116M.

In FY 2025, Voyager Therapeutics, Inc. reported revenue of $40M and earnings per share (EPS) of $-2.04. Net income for the quarter was $-120M. Revenue grew -49.5% year-over-year compared to FY 2024. Operating income came in at $-132M.

In Q3 2025, Voyager Therapeutics, Inc. reported revenue of $13M and earnings per share (EPS) of $-0.47. Net income for the quarter was $-28M. Revenue grew -45.7% year-over-year compared to Q3 2024. Operating income came in at $-31M.

In Q2 2025, Voyager Therapeutics, Inc. reported revenue of $5M and earnings per share (EPS) of $-0.57. Net income for the quarter was $-33M. Revenue grew -82.4% year-over-year compared to Q2 2024. Operating income came in at $-37M.

Over the past 8 quarters, Voyager Therapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $30M to $50M. Investors analyzing VYGR stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

VYGR Dividend Yield and Income Analysis

Voyager Therapeutics, Inc. (VYGR) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

VYGR Momentum and Technical Analysis Profile

Voyager Therapeutics, Inc. (VYGR) has a momentum factor score of 39/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 39/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 50/100 reflects moderate short selling activity.

VYGR vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Voyager Therapeutics, Inc. (VYGR) ranks #409 out of 838 stocks based on the Blank Capital composite score. This places VYGR in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing VYGR against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full VYGR vs S&P 500 (SPY) comparison to assess how Voyager Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

VYGR Next Earnings Date

No upcoming earnings date has been announced for Voyager Therapeutics, Inc. (VYGR) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy VYGR? — Investment Thesis Summary

The quantitative profile for Voyager Therapeutics, Inc. suggests caution. The quality score of 23/100 flags below-average profitability. The value score of 13/100 indicates premium valuation. Momentum is weak at 39/100, a headwind for near-term performance. High volatility (stability score 30/100) increases portfolio risk.

In summary, Voyager Therapeutics, Inc. (VYGR) earns a Reduce rating with a composite score of 30.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on VYGR stock.

Related Resources for VYGR Investors

Explore more research and tools: VYGR vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare VYGR head-to-head with peers: VYGR vs AZN, VYGR vs SLGL, VYGR vs VMD.